ANI Pharmaceuticals (ANIP) Earns Coverage Optimism Rating of 0.20

News headlines about ANI Pharmaceuticals (NASDAQ:ANIP) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ANI Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.3700798665555 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

ANI Pharmaceuticals (NASDAQ:ANIP) traded up 0.68% during trading on Tuesday, hitting $51.50. The company had a trading volume of 20,208 shares. The company’s 50 day moving average price is $46.37 and its 200-day moving average price is $48.01. ANI Pharmaceuticals has a 12 month low of $42.23 and a 12 month high of $69.85. The company has a market cap of $599.36 million, a PE ratio of 112.69 and a beta of 3.10.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.19. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. ANI Pharmaceuticals’s quarterly revenue was up 43.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.11 earnings per share. Equities analysts expect that ANI Pharmaceuticals will post $3.84 earnings per share for the current year.

ANIP has been the subject of several recent research reports. BidaskClub raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 price objective on shares of ANI Pharmaceuticals in a research report on Wednesday, August 9th. ValuEngine lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Guggenheim restated a “buy” rating and set a $80.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. Finally, Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $65.33.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply